Welcome to the our Aesthetic Medicine news roundup, 12 August 2022.
Key Collaboration and Distribution Agreement Signed With Major Partner To Advance Sofwave™ Sales In China’s Growing $29 Billion Aesthetic Medicine Market
Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that it has entered a key collaboration and distribution agreement with HTDK Group to advance Sofwave™ sales in China. This strategic partnership will be an important step for Sofwave to tap into the rapidly growing market.
Galderma launches new campaign for injectables at PrideFest
Galderma officially kicked off its latest campaign for Restylane injectables at New York City’s PrideFest on Sunday.
Dr Constantino Mendieta Awarded #1 on Newsweek’s America’s Best Plastic Surgeons 2022 List
Constantino Mendieta MD, 4 Beauty Aesthetic Institute for Plastic Surgery has been awarded #1 on Newsweek’s list of America’s Best Plastic Surgeons 2022. This prestigious award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider.
Three Cosmetic Surgery Deaths in Tijuana Raises Alarm About Illegal Clinics
In Tijuana, three people died from cosmetic surgeries in the last month, raising the alarm about illegal clinics in Mexico’s main medical tourism destination, especially for Americans.
Will a biotech rival finally shake up AbbVie’s $2B Botox cosmetic franchise? Revance will find out soon
For 20 years, Botox — short for the neurotoxic protein botulinum toxin — has reigned supreme as the most popular cosmetic procedure. Even as Evolus managed to score an FDA approval for a rival product named Jeuveau, its 2021 sales of almost $100 million were no match for the $2.2 billion revenue AbbVie reported for Botox Cosmetic alone.
Plus-size models are driving a new plastic surgery trend: study
While traditional standards of beauty are evolving, people still have the desire to change their bodies to look like someone else.
Allergan, eyeing Asia for growth, pours $14.7M into first medical aesthetics center in China
Allergan’s ambition for its medical aesthetics business is to grow to about $8 billion in 2025 from $3.8 billion in 2017 sales, with a big chunk coming from Asia. To achieve that, the U.S. pharma will put a center in Chengdu, China, devoted to letting doctors and potential customers understand what medical aesthetics is all about.
